Literature DB >> 17553868

Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo.

Jörg Votteler1, Nicole Studtrucker, Stefan Sörgel, Jan Münch, Elke Rücker, Frank Kirchhoff, Bernhard Schick, Peter Henklein, Torgils Fossen, Karsten Bruns, Alok Sharma, Victor Wray, Ulrich Schubert.   

Abstract

Mutational analysis of the four conserved proline residues in human immunodeficiency virus type 1 (HIV-1) Vpr reveals that only Pro-35 is required for efficient replication of R5-tropic, but not of X4-tropic, viruses in human lymphoid tissue (HLT) cultivated ex vivo. While Vpr-mediated apoptosis and G(2) cell cycle arrest, as well as the expression and subcellular localization of Vpr, were independent, the capacity for encapsidation of Vpr into budding virions was dependent on Pro-35. (1)H nuclear magnetic resonance data suggest that mutation of Pro-35 causes a conformational change in the hydrophobic core of the molecule, whose integrity is required for the encapsidation of Vpr, and thus, Pro-35 supports the replication of R5-tropic HIV-1 in HLT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17553868      PMCID: PMC1951402          DOI: 10.1128/JVI.02803-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Authors:  S P Singh; B Tomkowicz; D Lai; M Cartas; S Mahalingam; V S Kalyanaraman; R Murali; A Srinivasan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag).

Authors:  Y Jenkins; O Pornillos; R L Rich; D G Myszka; W I Sundquist; M H Malim
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 3.  Insights into the biology of HIV-1 viral protein R.

Authors:  Michael P Sherman; Carlos M C De Noronha; Samuel A Williams; Warner C Greene
Journal:  DNA Cell Biol       Date:  2002-09       Impact factor: 3.311

4.  Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr.

Authors:  C M de Noronha; M P Sherman; H W Lin; M V Cavrois; R D Moir; R D Goldman; W C Greene
Journal:  Science       Date:  2001-11-02       Impact factor: 47.728

5.  NMR structure of the (1-51) N-terminal domain of the HIV-1 regulatory protein Vpr.

Authors:  K Wecker; B P Roques
Journal:  Eur J Biochem       Date:  1999-12

6.  Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than gag and is phosphorylated in infected cells.

Authors:  B Müller; U Tessmer; U Schubert; H G Kräusslich
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Solution structure of the human immunodeficiency virus type 1 p6 protein.

Authors:  Torgils Fossen; Victor Wray; Karsten Bruns; Judhi Rachmat; Peter Henklein; Uwe Tessmer; Annette Maczurek; Patricia Klinger; Ulrich Schubert
Journal:  J Biol Chem       Date:  2005-10-17       Impact factor: 5.157

8.  Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism.

Authors:  Armin Papkalla; Jan Münch; Claas Otto; Frank Kirchhoff
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Effect of R77Q, R77A and R80A changes in Vpr on HIV-1 replication and CD4 T cell depletion in human lymphoid tissue ex vivo.

Authors:  Devi Rajan; Steffen Wildum; Elke Rücker; Michael Schindler; Frank Kirchhoff
Journal:  AIDS       Date:  2006-04-04       Impact factor: 4.177

10.  NMR structure of the HIV-1 regulatory protein Vpr in H2O/trifluoroethanol. Comparison with the Vpr N-terminal (1-51) and C-terminal (52-96) domains.

Authors:  K Wecker; N Morellet; S Bouaziz; B P Roques
Journal:  Eur J Biochem       Date:  2002-08
View more
  9 in total

1.  The intriguing cyclophilin A-HIV-1 Vpr interaction: prolyl cis/trans isomerisation catalysis and specific binding.

Authors:  Sara M Solbak; Tove R Reksten; Victor Wray; Karsten Bruns; Ole Horvli; Arnt J Raae; Petra Henklein; Peter Henklein; Rene Röder; David Mitzner; Ulrich Schubert; Torgils Fossen
Journal:  BMC Struct Biol       Date:  2010-10-04

2.  Human immunodeficiency virus type 1 Vpr: oligomerization is an essential feature for its incorporation into virus particles.

Authors:  Narasimhan J Venkatachari; Leah A Walker; Oznur Tastan; Thien Le; Timothy M Dempsey; Yaming Li; Naveena Yanamala; Alagarsamy Srinivasan; Judith Klein-Seetharaman; Ronald C Montelaro; Velpandi Ayyavoo
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

3.  Characterization of a novel type of HIV-1 particle assembly inhibitor using a quantitative luciferase-Vpr packaging-based assay.

Authors:  Gaëlle Gonzalez; Sandrina DaFonseca; Elisabeth Errazuriz; Pascale Coric; Florence Souquet; Serge Turcaud; Pierre Boulanger; Serge Bouaziz; Saw See Hong
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

4.  The host-pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains.

Authors:  Sara M Ø Solbak; Victor Wray; Ole Horvli; Arnt J Raae; Marte I Flydal; Petra Henklein; Peter Henklein; Manfred Nimtz; Ulrich Schubert; Torgils Fossen
Journal:  BMC Struct Biol       Date:  2011-12-20

5.  The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.

Authors:  Sandrina Dafonseca; Pascale Coric; Bernard Gay; Saw See Hong; Serge Bouaziz; Pierre Boulanger
Journal:  Virol J       Date:  2008-12-23       Impact factor: 4.099

6.  Solution structure of the equine infectious anemia virus p9 protein: a rationalization of its different ALIX binding requirements compared to the analogous HIV-p6 protein.

Authors:  Alok Sharma; Karsten Bruns; René Röder; Peter Henklein; Jörg Votteler; Victor Wray; Ulrich Schubert
Journal:  BMC Struct Biol       Date:  2009-12-17

7.  A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: potential impact on CTL epitopes.

Authors:  Alagarsamy Srinivasan; Velpandi Ayyavoo; Sundarasamy Mahalingam; Aarthi Kannan; Anne Boyd; Debduti Datta; Vaniambadi S Kalyanaraman; Anthony Cristillo; Ronald G Collman; Nelly Morellet; Bassel E Sawaya; Ramachandran Murali
Journal:  Virol J       Date:  2008-08-23       Impact factor: 4.099

8.  Virion encapsidated HIV-1 Vpr induces NFAT to prime non-activated T cells for productive infection.

Authors:  Kristin Höhne; Ramona Businger; Anouk van Nuffel; Sebastian Bolduan; Herwig Koppensteiner; Ann Baeyens; Jolien Vermeire; Eva Malatinkova; Bruno Verhasselt; Michael Schindler
Journal:  Open Biol       Date:  2016-07       Impact factor: 6.411

9.  Dual role of the chromatin-binding factor PHF13 in the pre- and post-integration phases of HIV-1 replication.

Authors:  Stephan Hofmann; Sandra Dehn; Ramona Businger; Sebastian Bolduan; Martha Schneider; Zeger Debyser; Ruth Brack-Werner; Michael Schindler
Journal:  Open Biol       Date:  2017-10       Impact factor: 6.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.